Brookline Capital Management Forecasts Imunon Q1 Earnings

Imunon, Inc. (NASDAQ:IMNN) – Analysts at Brookline Capital Management issued their Q1 2025 earnings per share estimates for shares of Imunon in a report released on Thursday, November 7th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn ($0.33) per share for the quarter. The consensus estimate for Imunon’s current full-year earnings is ($1.71) per share. Brookline Capital Management also issued estimates for Imunon’s Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.29) EPS and Q4 2025 earnings at ($0.30) EPS.

Imunon (NASDAQ:IMNN) last issued its earnings results on Wednesday, August 14th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.04.

Other equities analysts also recently issued reports about the company. HC Wainwright decreased their target price on Imunon from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Monday. EF Hutton Acquisition Co. I upgraded Imunon to a “strong-buy” rating in a research report on Monday, September 23rd.

Imunon Stock Performance

NASDAQ IMNN opened at $0.78 on Monday. Imunon has a one year low of $0.48 and a one year high of $3.65. The company has a 50-day simple moving average of $1.01 and a 200-day simple moving average of $1.19. The firm has a market capitalization of $46.56 million, a PE ratio of -0.44 and a beta of 2.14.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.